Table 1 Presentation of baseline data, laboratory results and outcome of 203 CLL patients

From: Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients

Variable Mutated Unmutated All samples P
Number of patients 128 74 203  
Gender (M/F) 80/48 51/23 132/71 0.35
Age, mean (s.d.) years 60.9 (8.0) 62.2 (7.5) 61.4 (7.8) 0.30
Binet stage (A/B/C) 106/12/6 45/22/4 151/31/10 0.0007
Rai stage (0/I/II/III/IV) 67/42/9/4/2 17/36/9/6/3 84/79/18/10/5 0.00007
Hemoglobin level (g/l) 136 (16) 132 (20) 135 (18) 0.3
Lymphocyte count ( × 10-9/l) 39 (50) 92 (145) 57 (97) 0.004
Platelet count ( × 10-9/l) 201 (60) 214 (98) 206 (76) 0.4
Treated (Y/N) 37/77 67/3 104/81 <0.000001
Alive (Y/N) 112/16 28/46 141/62 <0.000001
Recurrent aberrations (Y/N)     
del(13q) 83/45 27/47 110/93 0.0001
Homozygous del(13q) 22/106 1/73 23/180 0.0007
Trisomy 12 8/120 15/59 23/180 0.0025
del(11q) 4/124 23/51 27/176 <0.000001
del(17p) 1/127 8/66 9/194 0.0009
None 38/90 14/60 53/150  
CD38 % (s.d.) 8% (21) 27% (28) 15% (25) <0.000001
CD38 >20% (Y/N) 15/113 35/39 50/153 <0.000001
Average number of CNAs <1 Mbp 0.9 0.8 0.9 0.42
Average number of CNAs 1–5 Mbp 0.5 0.7 0.6 0.16
Average number of CNAs >5 Mbp 0.3 1.5 0.8 <0.000001
  1. Abbreviations: M/F, males/females; Y/N, yes/no.
  2. The number of patients or mean values (s.d.) are presented. One patient had undetermined IGHV mutation status. P-values indicate comparison between values for the mutated and the unmutated groups, as calculated with Mann–Whitney U-test.